Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · IEX Real-Time Price · USD

42.55

-0.23 (-0.54%)

At close: Jul 19, 2024, 4:00 PM

42.50

-0.05 (-0.12%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Revenue	442.59	434.25	363.33	351.41	271.03	103.71	Upgrade
Revenue Growth (YoY)	15.29%	19.52%	3.39%	29.66%	161.32%	101.41%	Upgrade
Cost of Revenue	50.49	45.21	28.32	16.01	6.13	9.01	Upgrade
Gross Profit	392.1	389.04	335.01	335.4	264.9	94.71	Upgrade
Selling, General & Admin	311.31	309.8	278.14	219.98	182.93	161.52	Upgrade
Research & Development	661.24	648.45	705.79	497.15	412.08	357.36	Upgrade
Other Operating Expenses	0.65	0.34	1.57	1.69	0	0	Upgrade
Operating Expenses	973.2	958.59	985.49	718.82	595.02	518.88	Upgrade
Operating Income	-581.1	-569.55	-650.49	-383.42	-330.12	-424.17	Upgrade
Other Expense / Income	34.12	38.92	51.24	69.56	-144.76	-24.73	Upgrade
Pretax Income	-615.22	-608.46	-701.73	-452.98	-185.36	-399.44	Upgrade
Income Tax	-1.87	-1.83	5.7	1.04	1.21	3.28	Upgrade
Net Income	-613.35	-606.64	-707.42	-454.03	-186.57	-402.73	Upgrade
Shares Outstanding (Basic)	84	74	70	68	61	57	Upgrade
Shares Outstanding (Diluted)	84	74	70	68	61	57	Upgrade
Shares Change	19.78%	5.19%	3.13%	11.42%	7.54%	13.66%	Upgrade
EPS (Basic)	-7.95	-8.25	-10.12	-6.70	-3.07	-7.12	Upgrade
EPS (Diluted)	-7.95	-8.25	-10.12	-6.70	-3.07	-7.12	Upgrade
Free Cash Flow	-531.11	-519.07	-496.59	-411.79	-176.13	-370.22	Upgrade
Free Cash Flow Per Share	-6.30	-7.06	-7.10	-6.07	-2.90	-6.54	Upgrade
Gross Margin	88.59%	89.59%	92.21%	95.44%	97.74%	91.31%	Upgrade
Operating Margin	-131.30%	-131.16%	-179.03%	-109.11%	-121.80%	-408.98%	Upgrade
Profit Margin	-138.58%	-139.70%	-194.71%	-129.20%	-68.84%	-388.31%	Upgrade
Free Cash Flow Margin	-120.00%	-119.53%	-136.68%	-117.18%	-64.98%	-356.96%	Upgrade
EBITDA	-585.6	-582.46	-683.51	-439.74	-173.1	-390.91	Upgrade
EBITDA Margin	-132.31%	-134.13%	-188.12%	-125.14%	-63.87%	-376.91%	Upgrade
Depreciation & Amortization	29.62	26.01	18.22	13.24	12.26	8.54	Upgrade
EBIT	-615.22	-608.46	-701.73	-452.98	-185.36	-399.44	Upgrade
EBIT Margin	-139.00%	-140.12%	-193.14%	-128.91%	-68.39%	-385.14%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).